Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1,297.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,657 shares of the company's stock after purchasing an additional 14,537 shares during the period. Jacobs Levy Equity Management Inc. owned approximately 0.05% of Medpace worth $5,202,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after purchasing an additional 25,704 shares during the period. Invesco Ltd. grew its position in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after buying an additional 519,186 shares during the period. Wasatch Advisors LP grew its position in Medpace by 3.1% during the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after buying an additional 28,161 shares during the period. Geode Capital Management LLC lifted its holdings in Medpace by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after purchasing an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Medpace by 15.0% during the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock worth $191,379,000 after acquiring an additional 75,275 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 0.7%

Shares of Medpace stock traded down $2.16 on Monday, reaching $303.50. The stock had a trading volume of 105,119 shares, compared to its average volume of 350,347. The company has a 50 day moving average price of $304.24 and a 200 day moving average price of $327.86. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The stock has a market capitalization of $8.72 billion, a P/E ratio of 24.03, a P/E/G ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. During the same quarter in the previous year, the firm earned $3.20 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the business's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at $904,856.36. The trade was a 36.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 20.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MEDP. Leerink Partners started coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Robert W. Baird decreased their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. Mizuho decreased their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.